PAB's in such a hot space with all the big pharma deals of late even on pre-clinical assets- locking the patents down around it installs plenty of value - this little snippet at the end appears to show they are right on top of their game.
"Patrys has granted or pending patents in major jurisdictions where future regulatory approvals and product sales are targeted, and currently has more than 19 patent applications pending across 10 different patent families."
Ann: First patent granted for Deoxymab-nanoparticles, page-5
-
- There are more pages in this discussion • 27 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $9.258M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 11 | 24181784 | 0.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.5¢ | 7489761 | 10 |
View Market Depth
| Last trade - 16.12pm 12/11/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable